Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001326190-25-000034
Filing Date
2025-05-13
Accepted
2025-05-13 16:55:02
Documents
58
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alt-20250331x10q.htm   iXBRL 10-Q 942662
2 EX-10.3 alt-20250331xex10d3.htm EX-10.3 752968
3 EX-31.1 alt-20250331xex31d1.htm EX-31.1 11835
4 EX-31.2 alt-20250331xex31d2.htm EX-31.2 11666
5 EX-32.1 alt-20250331xex32d1.htm EX-32.1 6655
6 EX-32.2 alt-20250331xex32d2.htm EX-32.2 6773
7 GRAPHIC alt-20250331x10q002.jpg GRAPHIC 16725
  Complete submission text file 0001326190-25-000034.txt   5497474

Data Files

Seq Description Document Type Size
8 EX-101.SCH alt-20250331.xsd EX-101.SCH 33689
9 EX-101.CAL alt-20250331_cal.xml EX-101.CAL 39647
10 EX-101.DEF alt-20250331_def.xml EX-101.DEF 126845
11 EX-101.LAB alt-20250331_lab.xml EX-101.LAB 334871
12 EX-101.PRE alt-20250331_pre.xml EX-101.PRE 226499
61 EXTRACTED XBRL INSTANCE DOCUMENT alt-20250331x10q_htm.xml XML 634165
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32587 | Film No.: 25941041
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)